NUK - logo
E-resources
Peer reviewed Open access
  • Head and neck squamous cell...
    Beck, Tim N.; Smith, Chad H.; Flieder, Douglas B.; Galloway, Thomas J.; Ridge, John A.; Golemis, Erica A.; Mehra, Ranee; Chen, Amy

    Head & neck, March 2017, Volume: 39, Issue: 3
    Journal Article

    ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) is potentially curable, but treatment planning remains a challenge. Oncogenic human papillomavirus (HPV)‐positive disease is often associated with a good prognosis compared with HPV‐negative disease. However, some HPV‐positive HNSCC recurs, often with distant metastases and significant treatment resistance. Methods and Results We performed p16 immunohistochemistry (IHC), in situ hybridization (ISH) for high‐risk HPV, and comprehensive genomic profiling on oropharyngeal HNSCC with basaloid features and particularly aggressive disease course, noting a rare genetic event: a deleting mutation (exons 5–17) of the tumor suppressor and dominant cell cycle regulator retinoblastoma 1 (RB1). Genomic and transcriptomic data available through FoundationOne and The Cancer Genome Atlas (TCGA) were reviewed for additional HNSCC cases with RB1 alterations. Conclusion RB1 alterations may have important prognostic implications, particularly in the context of high p16 expression, in both HPV‐positive and HPV‐negative HNSCC. © 2016 Wiley Periodicals, Inc. Head Neck 39: E34–E39, 2017